Assistant Manager Editor Mike Klein spotlighted a press announcement from a Seattle-based biotech company called TapImmune Inc. working with Mayo Clinic this morning.
At that point, they were working with a Small Pox construct to create the vaccine for cancer as well as other infectious threats like, Ebola.
In May of this year, reports came out about Mayo Clinic's Dr. Edith Perez saying how this vaccine changed her view towards preventative medicine. She is working with TapImmune oon applying the vaccine to fight breast cancer.
TapImmune had only $142,000 in and $3.3 million in losses at that point in May.
This appears to be a promising company with deep ties to Mayo Clinic. It seems like a good candidate to based in Rochester rather than someplace like Seattle.
Here's some of what Klein filed on this for today's paper:
Seattle-based TapImmune Inc. has exercised its option agreement with Mayo Clinic to use its technology in a possible vaccine for certain types of cancer, it announced.
TapImmune signed a worldwide exclusive license agreement to commercialize a "proprietary folate receptor alpha vaccine technology for all cancer indications."
This technology, developed in the laboratory of Keith Knutson at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer. The trial demonstrated the experimental therapy was "safe, well-tolerated, provided a robust immune response," according to the news release. Next, TapImmune plans a Phase II clinical trial in the second half of the year.
TapImmune CEO Dr. Glynn Wilson said the company's future clinical programs will be "aimed at developing this leading vaccine candidate as a stand-alone therapy or in combination with other immunotherapies."
Mayo Clinic has a financial interest in the technology.